Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.

Bevacizumab treatment can result in tumor shrinkage of progressive vestibular schwannomas in some neurofibromatosis 2 (NF2) patients but its effect on meningiomas has not been defined. To determine the clinical activity of bevacizumab against NF2-related meningiomas, we measured changes in volume of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fabio P Nunes, Vanessa L Merker, Dominique Jennings, Paul A Caruso, Emmanuelle di Tomaso, Alona Muzikansky, Fred G Barker, Anat Stemmer-Rachamimov, Scott R Plotkin
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f1f7da0af9c04824ac2ec64c9d11a7a4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f1f7da0af9c04824ac2ec64c9d11a7a4
record_format	dspace
spelling	oai:doaj.org-article:f1f7da0af9c04824ac2ec64c9d11a7a42021-11-18T07:52:25ZBevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.1932-620310.1371/journal.pone.0059941https://doaj.org/article/f1f7da0af9c04824ac2ec64c9d11a7a42013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23555840/?tool=EBIhttps://doaj.org/toc/1932-6203Bevacizumab treatment can result in tumor shrinkage of progressive vestibular schwannomas in some neurofibromatosis 2 (NF2) patients but its effect on meningiomas has not been defined. To determine the clinical activity of bevacizumab against NF2-related meningiomas, we measured changes in volume of meningiomas in NF2 patients who received bevacizumab for treatment of progressive vestibular schwannomas. A radiographic response was defined as a 20% decrease in tumor size by volumetric MRI analysis. In addition, we determined the expression pattern of growth factors associated with tumor angiogenesis in paraffin-embedded tissues from 26 unrelated meningiomas. A total of 48 meningiomas in 15 NF2 patients were included in this study with a median follow up time of 18 months. A volumetric radiographic response was seen in 29% of the meningiomas (14/48). Tumor shrinkage was not durable: the median duration of response was 3.7 months and the median time to progression was 15 months. There was no significant correlation between pre-treatment growth rate and meningioma response in regression models. Tissue analysis showed no correlation between tumor microvascular density and expression of VEGF pathway components. This data suggests that, in contrast to schwannomas, activation of VEGF pathway is not the primary driver of angiogenesis in meningiomas. Our results suggest that a minority of NF2-associated meningiomas shrink during bevacizumab therapy and that these responses were of short duration. These results are comparable to previous studies of bevacizumab in sporadic meningiomas.Fabio P NunesVanessa L MerkerDominique JenningsPaul A CarusoEmmanuelle di TomasoAlona MuzikanskyFred G BarkerAnat Stemmer-RachamimovScott R PlotkinPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 3, p e59941 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Fabio P Nunes Vanessa L Merker Dominique Jennings Paul A Caruso Emmanuelle di Tomaso Alona Muzikansky Fred G Barker Anat Stemmer-Rachamimov Scott R Plotkin Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
description	Bevacizumab treatment can result in tumor shrinkage of progressive vestibular schwannomas in some neurofibromatosis 2 (NF2) patients but its effect on meningiomas has not been defined. To determine the clinical activity of bevacizumab against NF2-related meningiomas, we measured changes in volume of meningiomas in NF2 patients who received bevacizumab for treatment of progressive vestibular schwannomas. A radiographic response was defined as a 20% decrease in tumor size by volumetric MRI analysis. In addition, we determined the expression pattern of growth factors associated with tumor angiogenesis in paraffin-embedded tissues from 26 unrelated meningiomas. A total of 48 meningiomas in 15 NF2 patients were included in this study with a median follow up time of 18 months. A volumetric radiographic response was seen in 29% of the meningiomas (14/48). Tumor shrinkage was not durable: the median duration of response was 3.7 months and the median time to progression was 15 months. There was no significant correlation between pre-treatment growth rate and meningioma response in regression models. Tissue analysis showed no correlation between tumor microvascular density and expression of VEGF pathway components. This data suggests that, in contrast to schwannomas, activation of VEGF pathway is not the primary driver of angiogenesis in meningiomas. Our results suggest that a minority of NF2-associated meningiomas shrink during bevacizumab therapy and that these responses were of short duration. These results are comparable to previous studies of bevacizumab in sporadic meningiomas.
format	article
author	Fabio P Nunes Vanessa L Merker Dominique Jennings Paul A Caruso Emmanuelle di Tomaso Alona Muzikansky Fred G Barker Anat Stemmer-Rachamimov Scott R Plotkin
author_facet	Fabio P Nunes Vanessa L Merker Dominique Jennings Paul A Caruso Emmanuelle di Tomaso Alona Muzikansky Fred G Barker Anat Stemmer-Rachamimov Scott R Plotkin
author_sort	Fabio P Nunes
title	Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
title_short	Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
title_full	Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
title_fullStr	Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
title_full_unstemmed	Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
title_sort	bevacizumab treatment for meningiomas in nf2: a retrospective analysis of 15 patients.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/f1f7da0af9c04824ac2ec64c9d11a7a4
work_keys_str_mv	AT fabiopnunes bevacizumabtreatmentformeningiomasinnf2aretrospectiveanalysisof15patients AT vanessalmerker bevacizumabtreatmentformeningiomasinnf2aretrospectiveanalysisof15patients AT dominiquejennings bevacizumabtreatmentformeningiomasinnf2aretrospectiveanalysisof15patients AT paulacaruso bevacizumabtreatmentformeningiomasinnf2aretrospectiveanalysisof15patients AT emmanuelleditomaso bevacizumabtreatmentformeningiomasinnf2aretrospectiveanalysisof15patients AT alonamuzikansky bevacizumabtreatmentformeningiomasinnf2aretrospectiveanalysisof15patients AT fredgbarker bevacizumabtreatmentformeningiomasinnf2aretrospectiveanalysisof15patients AT anatstemmerrachamimov bevacizumabtreatmentformeningiomasinnf2aretrospectiveanalysisof15patients AT scottrplotkin bevacizumabtreatmentformeningiomasinnf2aretrospectiveanalysisof15patients
_version_	1718422887656849408

Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.

Ejemplares similares